Hansoh Pharma's HS-20093 Osteosarcoma Marketing Application Accepted by China's NMPA

Stock News
Sep 24

On September 24, 2026, Hansoh Pharma (03692) announced that the marketing application for its innovative drug, HS-20093 for injection (recombinant anti-B7-H3 antibody-drug conjugate), has been accepted by China's National Medical Products Administration (NMPA).

The application seeks approval for the treatment of osteosarcoma patients aged 12 years and older who have failed at least two prior lines of therapy.

HS-20093 for injection is a B7-H3-targeted antibody-drug conjugate (ADC) independently developed by the group.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10